Medical/Pharmaceuticals

Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial

- NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic infection - High level of vaccine efficacy maintained over a 6-month period of surveillance  - Continued reassuring safety profile in line with previous trials GAITHERSBURG, Md., March 1, 2022 /PRNewswire/ -- Novavax, In...

2022-03-01 05:01 4414

MIM Software Inc. Announces Global Partnership with GenesisCare

CLEVELAND, Feb. 28, 2022 /PRNewswire/ -- MIM Software Inc. announced today a partnership with leading global provider of integrated cancer care, GenesisCare, to increase patient access to world-class care on a global scale. GenesisCare's clinical teams treat more than 400,000 patients at more tha...

2022-02-28 23:15 2227

Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash

BENGALURU, India, Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris' biosimilars bus...

2022-02-28 22:15 4727

Inspira Technologies Applauded by Frost & Sullivan for Minimizing the Need for Invasive Mechanical Ventilation with Its Innovative Technology, the ART™ System

Inspira Technologies aims to set a new standard of care in the respiratory care industry by introducing its ART system. SAN ANTONIO, Feb. 28, 2022 /PRNewswire/ -- Frost & Sullivan recently analyzed the European artificial respiratory market and, based on its findings, recognizesInspira Technolog...

2022-02-28 22:00 2071

Argon Medical Devices Celebrates Its 50th Anniversary

Industry leader highlights its longevity and thanks employees for their loyalty and effort FRISCO, Texas, Feb. 28, 2022 /PRNewswire/ -- Argon Medical Devices, Inc., a leading manufacturer of medical devices for interventional procedures, announces its 50th anniversary. This impressive milestone ...

2022-02-28 18:00 3898

Transcenta Announces First Patient Dosed in Phase IIa Study of Claudin18.2 Monoclonal Antibody TST001 Combined with Cisplatin and Gemcitabine for the First Line Treatment of Biliary Tract Cancer

SUZHOU, China, Feb. 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the successful dosing...

2022-02-28 10:03 3653

First-ever Shingles Awareness Week highlights misconceptions about the risk of developing shingles among older adults, and the need for more education

* GSK has launched the inaugural Shingles Awareness Week to educate the general public about shingles in collaboration with the International Federation on Ageing * Over 90% of adults, above the age of 50, already carry the virus that causes shingles, and 1 in 3 adults will develop shingles i...

2022-02-28 10:00 2136

ALPS PHARMA LAUNCHES A NEW QUERCETIN DELIVERY COMPOSITION

HIDA, Japan, Feb. 28, 2022 /PRNewswire/ -- ALPS Pharmaceutical Ind. Co., Ltd.  (President:Osamu Ushimaru), a global pharmaceutical company pioneering phytochemicals in medicine and food,today announced the launch of a water-soluble Quercetin delivery composition, Eubioflavonoid® derived from Sopho...

2022-02-28 09:19 2046

ALPS PHARMA LAUNCHES A NEW WATER-SOLUBLE ISOQUERCETIN COMPOSITION WITH HIGHER ABSORPTION RATE

HIDA, Japan, Feb. 28, 2022 /PRNewswire/ -- ALPS Pharmaceutical Ind. Co., Ltd. (President:Osamu Ushimaru), a global pharmaceutical company that pioneered the use of phytochemicals in medicine and food, announced the launch of a new Isoquercetin composition, Eubio®Isoquercetin,today. Eubio®Isoqu...

2022-02-28 09:16 2152

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis

HANGZHOU, China, Feb. 28, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it had dosed the first patient with LNK01001 in its Phase II clinical trial on subjects with atopic dermatitis (A...

2022-02-28 08:00 4319

JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma

SHANGHAI, Feb. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the sup...

2022-02-27 18:30 7039

Jean-Luc Herbeaux to become Hovione CEO

LISBON, Portugal, Feb. 25, 2022 /PRNewswire/ -- Hovione today announced that the Board of Directors and the shareholders have approved the appointment of Dr. Jean-Luc Herbeaux as Hovione's Chief Executive Officer, effective1st April 2022.

2022-02-25 22:00 3744

Fosun Foundation's First Batch of 250,000 Sets of COVID-19 Rapid Antigen Test Kits Arrives in Hong Kong

HONG KONG, Feb. 25, 2022 /PRNewswire/ -- In an effort to support Hong Kong's fight against the severe fifth wave of COVID-19 epidemic, Fosun Foundation announced last week the donation ofHK$10 million anti-epidemic materials, including COVID-19 rapid antigen test kits and face masks toHong Kong. ...

2022-02-25 12:33 5743

Insilico Announces Successful Completion of Phase 0 Microdose Trial and Initiates Phase I Clinical Trial for its First AI-discovered Anti-fibrotic Product Candidate with Novel Target

NEW YORK and HONG KONG, Feb. 25, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that it has dosed multiple healthy volunteers in a Phase I clinical trial evaluating ISM001-055, the first anti-fibroti...

2022-02-25 00:00 5762

C2i Genomics Applauded by Frost & Sullivan for Enabling Real-time Cancer Monitoring Using Genomic Data with Its C2intelligence Platform

The C2intelligence Platform enables custom, cost-effective, efficient, automatic, and globally accessible cancer data management and real-time monitoring. SAN ANTONIO, Feb. 24, 2022 /PRNewswire/ -- Based on a recent industry analysis,Frost & Sullivan recognizes C2i Genomics with the 2022 North A...

2022-02-24 21:00 3461

SOPHiA GENETICS Launches New Deep Learning Capabilities to Support the Detection of Homologous Recombination Deficiencies

The SOPHiA DDM HRD Solution offers cost-effective, accurate, reliable, timely, and easily implementable in-house results to empower better clinical research decisions BOSTON and LAUSANNE, Switzerland, Feb. 24, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine,...

2022-02-24 20:57 2865

Seegene unveils new assay optimized for on-site testing in 'living with Covid-19' era

SEOUL, South Korea, Feb. 24, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530),  South Korea's leading molecular diagnostics company, today, announced the CE-IVD marking of its Allplex™ SARS-CoV-2 fast MDx Assay. This new assay is optimized for the 'living with COVID-19' era, where mass, swift and ...

2022-02-24 20:00 2989

India's Largest Digital Healthcare Company MediBuddy Raises USD 125 Million in Series C Funding

Largest funding round in the Digital Healthcare services space BANGALORE, India, Feb. 24, 2022 /PRNewswire/ -- MediBuddy, India's largest end-to-end digital healthcare platform, has raisedUSD 125 million in Series C funding fromQuadria Capital and Lightrock India along with participation from ex...

2022-02-24 18:57 3747

Dr Ivan Puah Reveals That Using Calcium Hydroxyapatite Injection (Radiesse(R)) Post Liposuction Can Improve Skin Laxity Significantly

SINGAPORE, Feb. 24, 2022 /PRNewswire/ -- Calcium hydroxyapatite, also known as CaHA, in Radiesse®️ is the first and only FDA-approved filler available that provides both immediate and natural-looking results. Besides reversing volume loss in the face and hands, Radiesse®️ also stimulates colla...

2022-02-24 18:54 3887

Elekta: Interim report, May-January 2021/22

STOCKHOLM, Feb. 24, 2022 /PRNewswire/ -- The demand for Elekta's solutions continued to be strong in the third quarter, the fifth consecutive quarter with underlying order growth, resulting in Elekta's strongest order backlog ever. However, the global supply chain challenges remained, and revenue...

2022-02-24 17:13 4068
1 ... 346347348349350351352 ... 381